Hua shows sustained benefit in diabetics with glucokinase activator

Hua announced Phase III follow-up data showing its first-in-class diabetes therapy led to sustained HbA1c reductions at one year -- a long-term effect that EVP and CFO George Lin told BioCentury hasn’t been observed with most other oral Type II diabetes drugs.

Hua Medicine Ltd. (HKEX:2552) reported results post-market Thursday from the open-label portion of the Chinese SEED (HMM0301) study of oral dorzagliatin monotherapy for Type II diabetes. Lin said a Chinese NDA submission is likely to happen early next year, after the expected YE20 completion of its Phase III HMM0302 trial of the GCK activator as an add-on to metformin...